ValueQ3, 24Q4, 24Q1, 25Q2, 25Q3, 25TTMSelling/general/admin expenses7.74 M5.47 M5.89 M8.88 M8.44 M28.68 MResearch & development23.66 M18.9 M21.48 M33.69 M28.61 M102.69 MOperating income30.33 M23.86 M26.62 M41.11 M34.28 M125.87 MNon-Operating Income, Total——————Interest expense, net of interest capitalized——————Non-Operating Income, excl. Interest Expenses——————Unusual income/expense——————Pretax income-30.44 M-23.01 M-27.08 M-41.76 M-33.16 M-125.01 MEquity in earnings——————Taxes07 0000117 K0124 KNon-controlling/minority interest——————After tax other income/expense-549 K672 K-465 K-537 K-12 K-342 KNet income before discontinued operations30.44 M23.02 M27.08 M41.88 M33.16 M125.13 MDiscontinued operations——————Net income30.44 M23.02 M27.08 M41.88 M33.16 M125.13 MDilution adjustment——————Preferred dividends——————Diluted net income available to common stockholders30.44 M23.02 M27.08 M41.88 M33.16 M125.13 MBasic earnings per share (Basic EPS)-1.6-0.23-0.26-0.31-0.24-1.04Diluted earnings per share (Diluted EPS)-1.6-0.23-0.26-0.31-0.24-1.04Average basic shares outstanding19.24 M97 M102.62 M118.55 M124.72 M442.88 MDiluted shares outstanding19.24 M97 M102.62 M118.55 M124.72 M442.88 MEBITDA——————EBIT——-30.9 M-47.08 M-37.96 M—Cost of revenue——4.29 M5.96 M3.68 M—Other cost of goods sold——4.29 M5.96 M3.68 M—Depreciation & amortization (cash flow)——————
DBV Technologies S.A. - American Depositary Shares
DBV Technologies SA is a publicly owned French biopharmaceutical firm headquartered in Bagneux, France. DBV Technologies is known for developing "Viaskin" technology for administering allergens or antigens to intact skin while avoiding any transfer to the blood. Viaskin Peanut clinical development has received Fast Track designation from the US Food and Drug Administration.